Report Library
View More
Gene, Cell, & RNA Therapy Landscape...
May 16, 2025
Epilepsy KOL Interview - France
May 16, 2025
Datamonitor Healthcare Oncology: Pa...
May 15, 2025
Datamonitor Healthcare Infectious D...
May 15, 2025
Datamonitor Healthcare Infectious D...
May 14, 2025
Datamonitor Healthcare CNS: Insomni...
May 13, 2025
Wet AMD KOL- US, South #2
May 12, 2025
Datamonitor Healthcare Oncology Dis...
May 9, 2025
2025 Biomedtracker Datamonitor Hea...
May 8, 2025
Wet AMD KOL- France
May 8, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
Datamonitor Healthcare Oncology: Ho...
May 27, 2025
Datamonitor Healthcare Other: Uteri...
May 27, 2025
2025 Biomedtracker Datamonitor Hea...
May 23, 2025
Ovarian Cancer - KOL Interview - US...
May 21, 2025
Datamonitor Healthcare Oncology Dis...
May 21, 2025
Datamonitor Healthcare CNS Disease ...
May 21, 2025
Datamonitor Healthcare I&I: Opioid-...
May 21, 2025
Gene, Cell, & RNA Therapy Landscape...
May 16, 2025
Epilepsy KOL Interview - France
May 16, 2025
Datamonitor Healthcare Oncology: Pa...
May 15, 2025
Datamonitor Healthcare Infectious D...
May 15, 2025
Datamonitor Healthcare Infectious D...
May 14, 2025
Datamonitor Healthcare CNS: Insomni...
May 13, 2025
Wet AMD KOL- US, South #2
May 12, 2025
Datamonitor Healthcare Oncology Dis...
May 9, 2025
2025 Biomedtracker Datamonitor Hea...
May 8, 2025
Wet AMD KOL- France
May 8, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
HIV Pre-Exposure Prophylaxis (HIV P...
May 27, 2025
Datamonitor Healthcare Oncology: Ho...
May 27, 2025
Datamonitor Healthcare Other: Uteri...
May 27, 2025
2025 Biomedtracker Datamonitor Hea...
May 23, 2025
Ovarian Cancer - KOL Interview - US...
May 21, 2025
Datamonitor Healthcare Oncology Dis...
May 21, 2025
Datamonitor Healthcare CNS Disease ...
May 21, 2025
Datamonitor Healthcare I&I: Opioid-...
May 21, 2025
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/23/25 | Bristol (BMY) | Opdivo for Gastric Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/23/25 | Pfizer (PFE) | Sasanlimab for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/23/25 | Imunon (IMNN) | IMNN-001 for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/23/25 | Arcus (RCUS) | Casdatifan for Renal Cell Cancer (RCC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/23/25 | Jiangsu Hengrui Pharmaceuticals (600276:SS) | Dalpiciclib for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
| 04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 05/03/2025 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
| 05/13/2025 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 05/13/2025 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |